Today, the CFO of Inovio Pharmaceuticals, Peter Kies, exercised options of Inovio Pharmaceuticals (NASDAQ: INO) for $155.3K. The options were close to expired and Peter Kies disposed stocks.
See today’s analyst top recommended stocks >>
Currently, Inovio Pharmaceuticals has an average volume of 637.4K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $11.00, reflecting a -59.4% downside.
The insider sentiment on Inovio Pharmaceuticals has been negative according to 22 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
